

Maria Gabriella Matera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4843893/publications.pdf>

Version: 2024-02-01

180
papers

5,023
citations

87843

38
h-index

133188

59
g-index

181
all docs

181
docs citations

181
times ranked

4407
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. <i>Chest</i> , 2016, 149, 1181-1196. | 0.4 | 206 |
| 2 | Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?. <i>Respiratory Medicine</i> , 2020, 168, 105996. | 1.3 | 143 |
| 3 | Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. <i>European Respiratory Review</i> , 2015, 24, 451-461. | 3.0 | 140 |
| 4 | The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. <i>Respiratory Medicine</i> , 2016, 117, 190-197. | 1.3 | 136 |
| 5 | Optimizing drug delivery in COPD: The role of inhaler devices. <i>Respiratory Medicine</i> , 2017, 124, 6-14. | 1.3 | 131 |
| 6 | Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 40, 95-103. | 1.1 | 112 |
| 7 | TNF- α inhibitors in asthma and COPD: We must not throw the baby out with the bath water. <i>Pulmonary Pharmacology and Therapeutics</i> , 2010, 23, 121-128. | 1.1 | 108 |
| 8 | Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2018, 52, 1801586. | 3.1 | 101 |
| 9 | Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. <i>European Journal of Pharmacology</i> , 2015, 761, 168-173. | 1.7 | 97 |
| 10 | Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. <i>Trends in Pharmacological Sciences</i> , 2011, 32, 495-506. | 4.0 | 84 |
| 11 | Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 414-423. | 1.3 | 80 |
| 12 | Pharmacological characterization of the interaction between acclidinium bromide and formoterol fumarate on human isolated bronchi. <i>European Journal of Pharmacology</i> , 2014, 745, 135-143. | 1.7 | 80 |
| 13 | Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 552-563. | 0.7 | 77 |
| 14 | Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 175-181. | 0.7 | 73 |
| 15 | Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. <i>Respiratory Research</i> , 2016, 17, 70. | 1.4 | 71 |
| 16 | Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 307-317. | 1.1 | 65 |
| 17 | Bronchodilators. <i>Clinics in Chest Medicine</i> , 2014, 35, 191-201. | 0.8 | 65 |
| 18 | Adding a LAMA to ICS/LABA Therapy. <i>Chest</i> , 2019, 155, 758-770. | 0.4 | 65 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Adherence to COPD treatment: Myth and reality. <i>Respiratory Medicine</i> , 2017, 129, 117-123. | 1.3 | 64 |
| 20 | Severe Asthma and Biological Therapy: When, Which, and for Whom. <i>Pulmonary Therapy</i> , 2020, 6, 47-66. | 1.1 | 63 |
| 21 | Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. <i>Respiratory Research</i> , 2017, 18, 26. | 1.4 | 60 |
| 22 | Canakinumab for the treatment of chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 31, 15-27. | 1.1 | 57 |
| 23 | Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. <i>Current Opinion in Pharmacology</i> , 2018, 40, 95-103. | 1.7 | 57 |
| 24 | Searching for the synergistic effect between acclidinium and formoterol: From bench to bedside. <i>Respiratory Medicine</i> , 2015, 109, 1305-1311. | 1.3 | 54 |
| 25 | Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 55, 804-814. | 1.4 | 54 |
| 26 | Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 148-158. | 1.1 | 54 |
| 27 | Brain natriuretic peptide: Much more than a biomarker. <i>International Journal of Cardiology</i> , 2016, 221, 1031-1038. | 0.8 | 51 |
| 28 | TSLP Inhibitors for Asthma: Current Status and Future Prospects. <i>Drugs</i> , 2020, 80, 449-458. | 4.9 | 51 |
| 29 | LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. <i>European Respiratory Review</i> , 2017, 26, 160043. | 3.0 | 50 |
| 30 | Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1133-1146. | 1.0 | 47 |
| 31 | Interaction between corticosteroids and muscarinic antagonists in human airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 36, 1-9. | 1.1 | 47 |
| 32 | Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle <i>ex vivo</i> . <i>British Journal of Pharmacology</i> , 2020, 177, 1150-1163. | 2.7 | 47 |
| 33 | Antitrypsin deficiency and chronic respiratory disorders. <i>European Respiratory Review</i> , 2020, 29, 190073. | 3.0 | 47 |
| 34 | Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 15-23. | 1.1 | 46 |
| 35 | Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdoesteine, carbocysteine, and N-acetylcysteine. <i>Respiratory Research</i> , 2019, 20, 104. | 1.4 | 45 |
| 36 | Prospects for COPD treatment. <i>Current Opinion in Pharmacology</i> , 2021, 56, 74-84. | 1.7 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. Trends in Pharmacological Sciences, 2019, 40, 452-463. | 4.0 | 42 |
| 38 | Efficacy and safety profile of xanthines in COPD: a network meta-analysis. European Respiratory Review, 2018, 27, 180010. | 3.0 | 41 |
| 39 | Pharmacological modulation of β_2 -adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulmonary Pharmacology and Therapeutics, 2010, 23, 1-8. | 1.1 | 39 |
| 40 | The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Discovery, 2016, 11, 733-744. | 2.5 | 39 |
| 41 | The Challenges of Precision Medicine in COPD. Molecular Diagnosis and Therapy, 2017, 21, 345-355. | 1.6 | 37 |
| 42 | Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opinion on Drug Safety, 2015, 14, 533-541. | 1.0 | 36 |
| 43 | Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. Drugs, 2016, 76, 1257-1270. | 4.9 | 36 |
| 44 | Protein Prenylation Contributes to the Effects of LPS on EFS-Induced Responses in Human Isolated Bronchi. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 704-710. | 1.4 | 35 |
| 45 | The influence of propofol, remifentanyl and lidocaine on the tone of human bronchial smooth muscle. Pulmonary Pharmacology and Therapeutics, 2013, 26, 325-331. | 1.1 | 35 |
| 46 | PDE inhibitors currently in early clinical trials for the treatment of asthma. Expert Opinion on Investigational Drugs, 2014, 23, 1267-1275. | 1.9 | 35 |
| 47 | The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. International Journal of COPD, 2017, Volume 12, 3469-3485. | 0.9 | 35 |
| 48 | Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respiratory Medicine, 2019, 154, 86-92. | 1.3 | 35 |
| 49 | Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. Respiratory Medicine, 2019, 153, 3-13. | 1.3 | 35 |
| 50 | Guidance on nebulization during the current COVID-19 pandemic. Respiratory Medicine, 2021, 176, 106236. | 1.3 | 35 |
| 51 | Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101841. | 1.1 | 32 |
| 52 | Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. European Journal of Pharmacology, 2015, 761, 383-390. | 1.7 | 31 |
| 53 | Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. Drugs, 2015, 75, 1575-1585. | 4.9 | 30 |
| 54 | Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1007-1013. | 1.5 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. <i>Respiratory Research</i> , 2018, 19, 65. | 1.4 | 30 |
| 56 | Multifaceted activity of N-acetylcysteine in chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 693-708. | 1.0 | 30 |
| 57 | Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 40, 15-21. | 1.1 | 29 |
| 58 | Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. <i>Drugs</i> , 2017, 77, 721-732. | 4.9 | 29 |
| 59 | Effects of chronic treatment with the new ultra-long-acting β_2 -adrenoceptor agonist indacaterol alone or in combination with the β_1 -adrenoceptor blocker metoprolol on cardiac remodeling. <i>British Journal of Pharmacology</i> , 2015, 172, 3627-3637. | 2.7 | 28 |
| 60 | Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. <i>Drug Safety</i> , 2016, 39, 501-508. | 1.4 | 28 |
| 61 | Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. <i>European Journal of Pharmacology</i> , 2017, 812, 147-154. | 1.7 | 28 |
| 62 | Controversy surrounding the Sputnik V vaccine. <i>Respiratory Medicine</i> , 2021, 187, 106569. | 1.3 | 28 |
| 63 | Role of muscarinic antagonists in asthma therapy. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 239-253. | 1.0 | 27 |
| 64 | Pharmacological treatment and current controversies in COPD. <i>F1000Research</i> , 2019, 8, 1533. | 0.8 | 27 |
| 65 | Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?. <i>Drugs</i> , 2014, 74, 1983-1992. | 4.9 | 26 |
| 66 | Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. <i>Respiratory Medicine</i> , 2016, 117, 150-153. | 1.3 | 26 |
| 67 | Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 261-264. | 1.0 | 26 |
| 68 | Enfentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 827-833. | 1.9 | 26 |
| 69 | Propofol protects against opioid-induced hyperresponsiveness of airway smooth muscle in a horse model of target-controlled infusion anaesthesia. <i>European Journal of Pharmacology</i> , 2015, 765, 463-471. | 1.7 | 25 |
| 70 | Tiotropium formulations and safety: a network meta-analysis. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 17-30. | 1.0 | 25 |
| 71 | Muscarinic Receptor Antagonists. <i>Handbook of Experimental Pharmacology</i> , 2016, 237, 41-62. | 0.9 | 24 |
| 72 | How does race/ethnicity influence pharmacological response to asthma therapies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 435-446. | 1.5 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | β2-Adrenoceptor signalling bias in asthma and COPD and the potential impact on the comorbidities associated with these diseases. <i>Current Opinion in Pharmacology</i> , 2018, 40, 142-146. | 1.7 | 24 |
| 74 | The future of bronchodilation: looking for new classes of bronchodilators. <i>European Respiratory Review</i> , 2019, 28, 190095. | 3.0 | 24 |
| 75 | Long-acting muscarinic antagonists and small airways in asthma: Which link?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1990-2001. | 2.7 | 24 |
| 76 | Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials. <i>Vaccines</i> , 2021, 9, 341. | 2.1 | 24 |
| 77 | Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. <i>Respiratory Medicine</i> , 2020, 171, 106114. | 1.3 | 23 |
| 78 | Advances with glucocorticoids in the treatment of asthma: state of the art. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2305-2316. | 0.9 | 23 |
| 79 | Emerging drugs for chronic obstructive pulmonary disease. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 61-82. | 1.0 | 22 |
| 80 | Cardiovascular disease in patients with COPD. <i>Lancet Respiratory Medicine</i> , 2015, 3, 593-595. | 5.2 | 22 |
| 81 | Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. <i>Respiratory Medicine</i> , 2015, 109, 1019-1025. | 1.3 | 21 |
| 82 | Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 56, 39-50. | 1.1 | 21 |
| 83 | Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. <i>Drugs</i> , 2020, 80, 1799-1809. | 4.9 | 21 |
| 84 | Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. <i>Life Sciences</i> , 2015, 131, 44-50. | 2.0 | 20 |
| 85 | Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 48, 185-194. | 1.1 | 20 |
| 86 | N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. <i>Biomedicine and Pharmacotherapy</i> , 2018, 103, 1-8. | 2.5 | 20 |
| 87 | Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. <i>Advances in Therapy</i> , 2019, 36, 3291-3298. | 1.3 | 18 |
| 88 | A potential role of triple therapy for asthma patients. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1079-1085. | 1.0 | 18 |
| 89 | Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways. <i>Pharmacological Research</i> , 2021, 172, 105801. | 3.1 | 18 |
| 90 | Novel glucocorticoid receptor agonists in the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1473-1482. | 1.9 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Fixed-Dose Combination Inhalers. Handbook of Experimental Pharmacology, 2016, 237, 117-129. | 0.9 | 17 |
| 92 | Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 526-532. | 0.7 | 17 |
| 93 | Impact of doxofylline in COPD: A pairwise meta-analysis. Pulmonary Pharmacology and Therapeutics, 2018, 51, 1-9. | 1.1 | 17 |
| 94 | Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab. British Journal of Pharmacology, 2020, 177, 4750-4765. | 2.7 | 17 |
| 95 | The latest on the role of LAMAs in asthma. Journal of Allergy and Clinical Immunology, 2020, 146, 1288-1291. | 1.5 | 17 |
| 96 | Prospects for severe asthma treatment. Current Opinion in Pharmacology, 2021, 56, 52-60. | 1.7 | 17 |
| 97 | Treatable Mechanisms in Asthma. Molecular Diagnosis and Therapy, 2021, 25, 111-121. | 1.6 | 17 |
| 98 | New Avenues for Phosphodiesterase Inhibitors in Asthma. Journal of Experimental Pharmacology, 2021, Volume 13, 291-302. | 1.5 | 17 |
| 99 | Preexisting cardiorespiratory comorbidity does not preclude the success of multidisciplinary rehabilitation in post-COVID-19 patients. Respiratory Medicine, 2021, 184, 106470. | 1.3 | 17 |
| 100 | Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101828. | 1.1 | 16 |
| 101 | Sex differences in COPD management. Expert Review of Clinical Pharmacology, 2021, 14, 323-332. | 1.3 | 16 |
| 102 | Use of Thiols in the Treatment of COVID-19: Current Evidence. Lung, 2021, 199, 335-343. | 1.4 | 16 |
| 103 | N-acetylcysteine in COPD may be beneficial, but for whom?. Lancet Respiratory Medicine, the, 2014, 2, 166-167. | 5.2 | 15 |
| 104 | Ultra-LABAs for the treatment of asthma. Respiratory Medicine, 2019, 156, 47-52. | 1.3 | 15 |
| 105 | Implications of the Adiponectin System in Non-Small Cell Lung Cancer Patients: A Case-Control Study. Biomolecules, 2020, 10, 926. | 1.8 | 15 |
| 106 | A review of the pharmacokinetics of M3 muscarinic receptor antagonists used for the treatment of asthma. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 143-148. | 1.5 | 15 |
| 107 | QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2015, 16, 1079-1090. | 0.9 | 14 |
| 108 | An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. Expert Review of Respiratory Medicine, 2018, 12, 43-54. | 1.0 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 28-37. | 1.1 | 13 |
| 110 | The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 589-596. | 1.0 | 13 |
| 111 | Monoclonal antibodies in severe asthma: is it worth it?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 517-520. | 1.5 | 13 |
| 112 | Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 737-750. | 0.9 | 13 |
| 113 | Bronchodilator therapy for chronic cough. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 47, 88-92. | 1.1 | 12 |
| 114 | POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes. <i>Chest</i> , 2018, 154, 746-748. | 0.4 | 12 |
| 115 | Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. <i>European Journal of Pharmacology</i> , 2018, 832, 114-119. | 1.7 | 12 |
| 116 | Bronchodilators in subjects with asthma-related comorbidities. <i>Respiratory Medicine</i> , 2019, 151, 43-48. | 1.3 | 12 |
| 117 | Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis. <i>Drugs</i> , 2022, 82, 1-13. | 4.9 | 12 |
| 118 | Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation. <i>Respiratory Medicine</i> , 2021, 182, 106401. | 1.3 | 11 |
| 119 | Brain natriuretic peptide modulates calcium homeostasis and epidermal growth factor receptor gene signalling in asthmatic airways smooth muscle cells. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 31, 51-54. | 1.1 | 10 |
| 120 | Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1101-1111. | 1.5 | 10 |
| 121 | Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. <i>Multidisciplinary Respiratory Medicine</i> , 2019, 14, 25. | 0.6 | 10 |
| 122 | An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 363-374. | 3.0 | 10 |
| 123 | Can FeNO be a biomarker in the post-COVID-19 patients monitoring?. <i>Respiratory Medicine</i> , 2022, 193, 106745. | 1.3 | 10 |
| 124 | Dual bronchodilation for the treatment of COPD: From bench to bedside. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3657-3673. | 1.1 | 10 |
| 125 | Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 977-988. | 0.9 | 9 |
| 126 | An update on the pharmacotherapeutic management of lower respiratory tract infections. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 973-988. | 0.9 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 239-245. | 1.5 | 9 |
| 128 | Drug interaction and chronic obstructive respiratory disorders. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100009. | 1.7 | 9 |
| 129 | Step-up and step-down approaches in the treatment of asthma. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1159-1168. | 1.0 | 9 |
| 130 | Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1415-1425. | 1.0 | 9 |
| 131 | Beyond Dual Bronchodilation – Triple Therapy, When and Why. <i>International Journal of COPD</i> , 2022, Volume 17, 165-180. | 0.9 | 9 |
| 132 | Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 35-41. | 1.3 | 8 |
| 133 | Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β_2 -Agonists in COPD: Accumulating Evidence from Network Meta-Analyses. <i>Pulmonary Therapy</i> , 2019, 5, 117-126. | 1.1 | 8 |
| 134 | Emerging muscarinic receptor antagonists for the treatment of asthma. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 123-130. | 1.0 | 8 |
| 135 | Classes of drugs that target the cellular components of inflammation under clinical development for COPD. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1015-1027. | 1.3 | 8 |
| 136 | The future of inhalation therapy in chronic obstructive pulmonary disease. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100092. | 1.7 | 8 |
| 137 | Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1805. | 0.9 | 7 |
| 138 | Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 791-793. | 2.0 | 7 |
| 139 | Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 813-822. | 1.5 | 7 |
| 140 | Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 88-94. | 1.1 | 7 |
| 141 | A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 60, 101883. | 1.1 | 7 |
| 142 | The role of triple therapy in the management of COPD. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 865-874. | 1.3 | 7 |
| 143 | Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 891-906. | 2.4 | 7 |
| 144 | Indacaterol for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 107-115. | 0.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Pharmacogenetic and pharmacogenomic considerations of asthma treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1159-1167. | 1.5 | 6 |
| 146 | A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 509-517. | 1.0 | 6 |
| 147 | Combining Dual Bronchodilation and β^2 -Blockade in Patients With an Overlap Between COPD and Cardiovascular Diseases. <i>Chest</i> , 2018, 153, 1289-1291. | 0.4 | 6 |
| 148 | The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. <i>Journal of Clinical Medicine</i> , 2020, 9, 2397. | 1.0 | 6 |
| 149 | Pharmacological management of adult patients with acute respiratory distress syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2169-2183. | 0.9 | 6 |
| 150 | <p>Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 261-271. | 0.4 | 6 |
| 151 | New perspectives on the role of muscarinic antagonists in asthma therapy. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 817-824. | 1.0 | 6 |
| 152 | Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 5-12. | 1.0 | 5 |
| 153 | Assessing the viability of long-acting β^2 -agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 129-136. | 1.5 | 5 |
| 154 | Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 2043-2053. | 0.9 | 5 |
| 155 | Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 723-738. | 1.9 | 5 |
| 156 | Management of COPD patients during COVID: difficulties and experiences. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1025-1033. | 1.0 | 4 |
| 157 | The Future of Bronchodilators in COPD and Asthma. <i>Archivos De Bronconeumologia</i> , 2022, 58, 107-108. | 0.4 | 4 |
| 158 | Disputes over the production and dissemination of misinformation in the time of COVID-19. <i>Respiratory Medicine</i> , 2021, 182, 106380. | 1.3 | 4 |
| 159 | An Obvious Paradigm. <i>Chest</i> , 2021, 160, 1157-1159. | 0.4 | 4 |
| 160 | Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today?. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 917-927. | 0.9 | 4 |
| 161 | An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1205-1216. | 0.9 | 4 |
| 162 | Specific role of combination acclidinium: formoterol in the treatment of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2016, 11, 73. | 0.9 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Isolated airways in equine respiratory pharmacology: They never lie. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 59, 101849. | 1.1 | 3 |
| 164 | Comparative studies of dual bronchodilation in COPD. <i>Monaldi Archives for Chest Disease</i> , 2021, 91, . | 0.3 | 3 |
| 165 | Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 357-365. | 1.0 | 3 |
| 166 | Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 20-26. | 1.1 | 2 |
| 167 | Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 621-635. | 1.0 | 2 |
| 168 | Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2020, 17, 215-223. | 0.7 | 2 |
| 169 | Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control?. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, . | 0.3 | 2 |
| 170 | Comments on "Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations" by D'Amato et al.. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 757. | 0.6 | 2 |
| 171 | Bronchodilators for Airway Disease. , 2022, , 712-728. | | 2 |
| 172 | Molecular aspects of asthma. <i>Molecular Aspects of Medicine</i> , 2022, 85, 101087. | 2.7 | 2 |
| 173 | Rebuttal From Drs Cazzola and Matera. <i>Chest</i> , 2018, 154, 751-752. | 0.4 | 1 |
| 174 | Response. <i>Chest</i> , 2019, 155, 1079-1080. | 0.4 | 1 |
| 175 | Current long-acting muscarinic antagonists for the treatment of asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-15. | 0.9 | 1 |
| 176 | Advances in the Pharmacological Management of Pediatric Acute Respiratory Distress Syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 349-360. | 0.9 | 1 |
| 177 | Acclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 771-777. | 1.3 | 0 |
| 178 | Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1093-1094. | 2.0 | 0 |
| 179 | Bronchodilator Response as a Possible Predictor of Lung Function Improvement After Pulmonary Rehabilitation in Post-COVID-19 Patients. <i>Archivos De Bronconeumologia</i> , 2021, , . | 0.4 | 0 |
| 180 | A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 269-283. | 1.3 | 0 |